VanEck Pharmaceutical ETFVanEck Pharmaceutical ETFVanEck Pharmaceutical ETF

VanEck Pharmaceutical ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪569.24 M‬USD
Fund flows (1Y)
‪124.01 M‬USD
Dividend yield (indicated)
1.98%
Discount/Premium to NAV
−0.03%
Shares outstanding
‪6.54 M‬
Expense ratio
0.36%

About VanEck Pharmaceutical ETF


Issuer
Van Eck Associates Corp.
Brand
VanEck
Home page
Inception date
Dec 20, 2011
Structure
Open-Ended Fund
Index tracked
MVIS US Listed Pharmaceutical 25
Management style
Passive
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
PPH provides exposure to the largest, US-listed multinational pharmaceutical giants in the world. The fund holds just 25 securities, including big weights in household names. Like the underlying pharmaceutical market, PPH is top heavy and has to reweight its big holdings to accommodate RIC diversification requirements, capping a single issuer to 20%. Still, it captures the space well, even after excluding Asia entirely. Overall, PPH is a great option for investors seeking exposure to big, multinational pharma companies. The index is reviewed on a semi-annual basis.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharmaceuticals
Strategy
Vanilla
Geography
Global
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of January 8, 2025
Exposure type
Stocks
Health Technology
Distribution Services
Stocks100.00%
Health Technology85.70%
Distribution Services14.30%
Bonds, Cash & Other0.00%
Stock breakdown by region
100%
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows